Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J.
Revenue (Most Recent Fiscal Year) | $0.02M |
Net Income (Most Recent Fiscal Year) | $-7.44M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.46 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -1312.60% |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -777.92% |
Return on Assets (Trailing 12 Months) | -271.32% |
Current Ratio (Most Recent Fiscal Quarter) | 1.03 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.03 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.21 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.89 |
Earnings per Share (Most Recent Fiscal Year) | $-11.35 |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 3.17M |
Free Float | 3.10M |
Market Capitalization | $3.74M |
Average Volume (Last 20 Days) | 0.03M |
Beta (Past 60 Months) | 0.95 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 2.00% |
Percentage Held By Institutions (Latest 13F Reports) | 9.45% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |